Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Other Accumulated Expenses (2016 - 2019)

Historic Other Accumulated Expenses for Viridian Therapeutics, Inc.\DE (VRDN) over the last 5 years, with Q1 2019 value amounting to $113000.0.

  • Viridian Therapeutics, Inc.\DE's Other Accumulated Expenses changed N/A to $113000.0 in Q1 2019 from the same period last year, while for Mar 2019 it was $113000.0, marking a year-over-year change of. This contributed to the annual value of $174000.0 for FY2018, which is N/A changed from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Other Accumulated Expenses stood at $113000.0 for Q1 2019.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Other Accumulated Expenses registered a high of $228000.0 during Q3 2016, and its lowest value of $83000.0 during Q2 2016.
  • In the last 4 years, Viridian Therapeutics, Inc.\DE's Other Accumulated Expenses had a median value of $102000.0 in 2015 and averaged $123000.0.
  • Examining YoY changes over the last 5 years, Viridian Therapeutics, Inc.\DE's Other Accumulated Expenses showed a top increase of 12574.26% in 2016 and a maximum decrease of 1530.61% in 2016.
  • Over the past 4 years, Viridian Therapeutics, Inc.\DE's Other Accumulated Expenses (Quarter) stood at $103000.0 in 2015, then surged by 43.69% to $148000.0 in 2016, then increased by 17.57% to $174000.0 in 2018, then crashed by 35.06% to $113000.0 in 2019.
  • Its last three reported values are $113000.0 in Q1 2019, $174000.0 for Q4 2018, and $148000.0 during Q4 2016.